(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management – leading to a solid cash position at the end of the First Quarter.”
The company maintained a strict management of its costs. The total cash position at the end of the Quarter was SEK 128.9 million.
The Quarter in Brief
PMDD: Our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD) made good progress, with a drop-out rate of less